Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Podcasts

Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like.

Episode 73: Biotech’s IPO Steamroll

Rich Horgan, founder and president of Cure Rare Disease (CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

Episode 72: Trying to Outpace Rare Disease

Sacha Ward, chief client officer of Point of Care Network, discusses how COVID has affected the roles of nurse practitioners and physician assistants, and why marketing managers should take a moment to understand this growing group of health care influencers.

Episode 71: Connecting With NPs and PAs

Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration. 

Episode 70: Keeping Pharma Informed

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

Episode 69: Fighting Influenza During COVID

Articles

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Episode 68: Rocking Garage Biotech

Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.

Episode 67: Succeeding Through Adversity

Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.

Episode 66: New Approach to Antithrombotics

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Episode 65: Creating a Path for Innovation

Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.

Episode 64: The Complexities of Managing ADHD

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times.

Episode 63: Three Simple Principles to Improve Leadership

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Episode 62: The Future of Pharma’s Supply Chain

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Episode 61: Preparing for Virtual High-Stakes Meetings

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.

Episode 60: Leading With Compassion

Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com

Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.

Episode 59: Using Tau to Target Alzheimer’s

Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.

Episode 58: Understanding FDA’s Gene Therapy Guidelines

Senior Editor, Elaine Quilici interviews Pratap Khedkar, managing principal of ZS Associates. Pratap talks about pharma’s scenario planning amid COVID-19 as it looks to settle into a new normal.

Episode 57: Planning for Pharma’s New Normal

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

Episode 56: Killing Cancer Through Direct Injection

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Episode 55: Developing a Maternal RSV Vaccine

Chris Paquette, DeepIntent co-founder and CEO, talks about the evolution of digital marketing in pharma, specifically, how to approach data and technology usage in a privacy-first world.

Editorial Podcasts